

Heidi M Mansour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9093188/publications.pdf>

Version: 2024-02-01

79
papers

3,190
citations

147801

31
h-index

155660

55
g-index

80
all docs

80
docs citations

80
times ranked

4037
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Design, Physicochemical Characterization, and In Vitro Permeation of Innovative Resatorvid Topical Formulations for Targeted Skin Drug Delivery. <i>Pharmaceutics</i> , 2022, 14, 700. | 4.5 | 4 |
| 2 | Design, Development, Physicochemical Characterization, and In Vitro Drug Release of Formoterol PEGylated PLGA Polymeric Nanoparticles. <i>Pharmaceutics</i> , 2022, 14, 638. | 4.5 | 6 |
| 3 | Glycosylated Ang-(1-7) MasR Agonist Peptide Poly Lactic-co-Glycolic Acid (PLGA) Nanoparticles and Microparticles in Cognitive Impairment: Design, Particle Preparation, Physicochemical Characterization, and In Vitro Release. <i>Pharmaceutics</i> , 2022, 14, 587. | 4.5 | 3 |
| 4 | Synthesis of alamandine glycoside analogs as new drug candidates to antagonize the MrgD receptor for pain relief. <i>Medicinal Chemistry Research</i> , 2022, 31, 1135-1146. | 2.4 | 3 |
| 5 | Kidney targeting of formoterol containing polymeric nanoparticles improves recovery from ischemia reperfusion-induced acute kidney injury in mice. <i>Kidney International</i> , 2022, 102, 1073-1089. | 5.2 | 8 |
| 6 | Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms. <i>Pharmaceutics</i> , 2022, 14, 1448. | 4.5 | 6 |
| 7 | Inhalable Nanoparticles/Microparticles of an AMPK and Nrf2 Activator for Targeted Pulmonary Drug Delivery as Dry Powder Inhalers. <i>AAPS Journal</i> , 2021, 23, 2. | 4.4 | 14 |
| 8 | To treat or not to treat: CFTR modulators after lung transplantation. <i>Pediatric Transplantation</i> , 2021, 25, e14007. | 1.0 | 12 |
| 9 | Design and Comprehensive Characterization of Tetramethylpyrazine (TMP) for Targeted Lung Delivery as Inhalation Aerosols in Pulmonary Hypertension (PH): In Vitro Human Lung Cell Culture and In Vivo Efficacy. <i>Antioxidants</i> , 2021, 10, 427. | 5.1 | 7 |
| 10 | Spray-Dried Inhalable Powder Formulations of Therapeutic Proteins and Peptides. <i>AAPS PharmSciTech</i> , 2021, 22, 185. | 3.3 | 24 |
| 11 | Formoterol PLGA-PEG Nanoparticles Induce Mitochondrial Biogenesis in Renal Proximal Tubules. <i>AAPS Journal</i> , 2021, 23, 88. | 4.4 | 13 |
| 12 | Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection. <i>Pharmaceutics</i> , 2021, 13, 1077. | 4.5 | 50 |
| 13 | Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers. <i>Pharmaceutics</i> , 2021, 13, 1278. | 4.5 | 9 |
| 14 | Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization, <i>in vitro</i> 2D/3D human lung cell cultures, and <i>in vivo</i> efficacy. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662199824. | 2.6 | 6 |
| 15 | Organic Solution Advanced Spray-Dried Microparticulate/Nanoparticulate Dry Powders of Lactomorphin for Respiratory Delivery: Physicochemical Characterization, In Vitro Aerosol Dispersion, and Cellular Studies. <i>Pharmaceutics</i> , 2021, 13, 26. | 4.5 | 9 |
| 16 | Angiotensin-(1-7) Peptide Hormone Reduces Inflammation and Pathogen Burden during <i>Mycoplasma pneumoniae</i> Infection in Mice. <i>Pharmaceutics</i> , 2021, 13, 1614. | 4.5 | 4 |
| 17 | Neurofilament light: a possible prognostic biomarker for treatment of vascular contributions to cognitive impairment and dementia. <i>Journal of Neuroinflammation</i> , 2021, 18, 236. | 7.2 | 7 |
| 18 | Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery. <i>Pharmaceutics</i> , 2021, 13, 2188. | 4.5 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Design and development of innovative microparticulate/nanoparticulate inhalable dry powders of a novel synthetic trifluorinated chalcone derivative and Nrf2 agonist. <i>Scientific Reports</i> , 2020, 10, 19771. | 3.3 | 4 |
| 20 | Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 64, 101975. | 2.6 | 21 |
| 21 | Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols. <i>RSC Advances</i> , 2020, 10, 41846-41856. | 3.6 | 11 |
| 22 | Urgent Appeal from International Society for Aerosols in Medicine (ISAM) During COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2020, 33, 235-238. | 1.4 | 27 |
| 23 | Comparison of L-Carnitine and L-Carnitine HCL salt for targeted lung treatment of pulmonary hypertension (PH) as inhalation aerosols: Design, comprehensive characterization, in vitro 2D/3D cell cultures, and in vivo MCT-Rat model of PH. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 65, 101998. | 2.6 | 4 |
| 24 | Sigh Syndrome in Pediatric Asthma. <i>Lung</i> , 2019, 197, 111-112. | 3.3 | 1 |
| 25 | Therapeutics in pulmonary hypertension. , 2019, , 313-322. | | 2 |
| 26 | Inhaled medical aerosols by nebulizer delivery in pulmonary hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-2. | 1.7 | 6 |
| 27 | Transfusion with packed red blood cells while awaiting lung transplantation is associated with reduced survival after lung transplantation. <i>Clinical Transplantation</i> , 2016, 30, 1545-1551. | 1.6 | 15 |
| 28 | Development of three-dimensional lung multicellular spheroids in air- and liquid-interface culture for the evaluation of anticancer therapeutics. <i>International Journal of Oncology</i> , 2016, 48, 1701-1709. | 3.3 | 32 |
| 29 | Microparticulate/nanoparticulate powders of a novel Nrf2 activator and an aerosol performance enhancer for pulmonary delivery targeting the lung Nrf2/Keap-1 pathway. <i>Molecular Systems Design and Engineering</i> , 2016, 1, 48-65. | 3.4 | 41 |
| 30 | Pulmonary Artery Pressure and Benefit of Lung Transplantation in Adult Cystic Fibrosis Patients. <i>Annals of Thoracic Surgery</i> , 2016, 101, 1104-1109. | 1.3 | 16 |
| 31 | Role of Nrf2 and Autophagy in Acute Lung Injury. <i>Current Pharmacology Reports</i> , 2016, 2, 91-101. | 3.0 | 77 |
| 32 | Prevalence of Pulmonary Hypertension and its Influence on Survival in Patients With Advanced Chronic Obstructive Pulmonary Disease Prior to Lung Transplantation. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 50-56. | 1.6 | 27 |
| 33 | Influence of Pulmonary Hypertension on Patients With Idiopathic Pulmonary Fibrosis Awaiting Lung Transplantation. <i>Annals of Thoracic Surgery</i> , 2016, 101, 246-252. | 1.3 | 47 |
| 34 | In Vitro Pulmonary Cell Culture in Pharmaceutical Inhalation Aerosol Delivery: 2-D, 3-D, and In Situ Bioimpactor Models. <i>Current Pharmaceutical Design</i> , 2016, 22, 2522-2531. | 1.9 | 17 |
| 35 | Inhalable nanoparticulate powders for respiratory delivery. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1189-1199. | 3.3 | 165 |
| 36 | Formulation and characterization of inhalable magnetic nanocomposite microparticles (MnMs) for targeted pulmonary delivery via spray drying. <i>International Journal of Pharmaceutics</i> , 2015, 479, 320-328. | 5.2 | 66 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Influence of Pulmonary Hypertension on Survival in Advanced Lung Disease. <i>Lung</i> , 2015, 193, 213-221. | 3.3 | 10 |
| 38 | Autophagy in neonatal hypoxia ischemic brain is associated with oxidative stress. <i>Redox Biology</i> , 2015, 6, 516-523. | 9.0 | 57 |
| 39 | Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 150, 707-713.e2. | 0.8 | 23 |
| 40 | Dry powder inhalers in COPD, lung inflammation and pulmonary infections. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 947-962. | 5.0 | 63 |
| 41 | Design, Characterization, and Aerosol Dispersion Performance Modeling of Advanced Spray-Dried Microparticulate/Nanoparticulate Mannitol Powders for Targeted Pulmonary Delivery as Dry Powder Inhalers. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2014, 27, 81-93. | 1.4 | 44 |
| 42 | Design, Characterization, and Aerosol Dispersion Performance Modeling of Advanced Co-Spray Dried Antibiotics with Mannitol as Respirable Microparticles/Nanoparticles for Targeted Pulmonary Delivery as Dry Powder Inhalers. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 2937-2949. | 3.3 | 29 |
| 43 | Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 52, 191-205. | 4.0 | 45 |
| 44 | Pulmonary Hypertension in Cystic Fibrosis with Advanced Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 898-905. | 5.6 | 62 |
| 45 | High-Performing Dry Powder Inhalers of Paclitaxel DPPC/DPPG Lung Surfactant-Mimic Multifunctional Particles in Lung Cancer: Physicochemical Characterization, In Vitro Aerosol Dispersion, and Cellular Studies. <i>AAPS PharmSciTech</i> , 2014, 15, 1574-1587. | 3.3 | 43 |
| 46 | Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers. <i>Pharmaceutics</i> , 2014, 6, 333-353. | 4.5 | 52 |
| 47 | Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 699-711. | 4.0 | 89 |
| 48 | Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. <i>International Journal of Pharmaceutics</i> , 2013, 455, 374-392. | 5.2 | 73 |
| 49 | Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery. <i>International Journal of Nanomedicine</i> , 2013, 8, 1269. | 6.7 | 26 |
| 50 | Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. <i>International Journal of Nanomedicine</i> , 2013, 8, 275. | 6.7 | 48 |
| 51 | Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation. <i>Drug Design, Development and Therapy</i> , 2013, 7, 59. | 4.3 | 30 |
| 52 | Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. <i>International Journal of Nanomedicine</i> , 2013, 8, 3489. | 6.7 | 28 |
| 53 | Phase behavior of itraconazole-phenol mixtures and its pharmaceutical applications. <i>International Journal of Pharmaceutics</i> , 2012, 436, 652-658. | 5.2 | 31 |
| 54 | Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery. <i>Lung</i> , 2012, 190, 251-262. | 3.3 | 119 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Advances in microscopy and complementary imaging techniques to assess the fate of drugs ex vivo in respiratory drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 344-356. | 13.7 | 30 |
| 56 | Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. <i>International Journal of Pharmaceutics</i> , 2012, 426, 193-201. | 5.2 | 163 |
| 57 | Particle Interactions in Dry Powder Inhaler Unit Processes: A Review. <i>Journal of Adhesion Science and Technology</i> , 2011, 25, 451-482. | 2.6 | 65 |
| 58 | Sustained-Release Delivery of Octreotide from Biodegradable Polymeric Microspheres. <i>AAPS PharmSciTech</i> , 2011, 12, 1293-1301. | 3.3 | 32 |
| 59 | Pulmonary and Nasal Anti-Inflammatory and Anti-Allergy Inhalation Aerosol Delivery Systems. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2011, 10, 215-229. | 1.1 | 11 |
| 60 | Nanopharmaceuticals II: application of nanoparticles and nanocarrier systems in pharmaceutics and nanomedicine. <i>International Journal of Nanotechnology</i> , 2011, 8, 115. | 0.2 | 18 |
| 61 | Physicochemical Characterization and Water Vapor Sorption of Organic Solution Advanced Spray-Dried Inhalable Trehalose Microparticles and Nanoparticles for Targeted Dry Powder Pulmonary Inhalation Delivery. <i>AAPS PharmSciTech</i> , 2011, 12, 1420-1430. | 3.3 | 34 |
| 62 | Improved Outcomes of Patients with End-stage Cystic Fibrosis Requiring Invasive Mechanical Ventilation for Acute Respiratory Failure. <i>Lung</i> , 2011, 189, 409-15. | 3.3 | 7 |
| 63 | Nanopharmaceuticals I: nanocarrier systems in drug delivery. <i>International Journal of Nanotechnology</i> , 2011, 8, 84. | 0.2 | 26 |
| 64 | Heterogeneous Particle Deaggregation and Its Implication for Therapeutic Aerosol Performance. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 3442-3461. | 3.3 | 26 |
| 65 | Dry Powder Aerosols Generated by Standardized Entrainment Tubes From Drug Blends With Lactose Monohydrate: 2. Ipratropium Bromide Monohydrate and Fluticasone Propionate. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 3415-3429. | 3.3 | 35 |
| 66 | Dry Powder Aerosols Generated by Standardized Entrainment Tubes from Alternative Sugar Blends: 3. Trehalose Dihydrate and d-Mannitol Carriers. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 3430-3441. | 3.3 | 31 |
| 67 | Dry Powder Aerosols Generated by Standardized Entrainment Tubes From Drug Blends With Lactose Monohydrate: 1. Albuterol Sulfate and Disodium Cromoglycate. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 3398-3414. | 3.3 | 30 |
| 68 | Surface Analytical Techniques in Solid-State Particle Characterization for Predicting Performance in Dry Powder Inhalers. <i>KONA Powder and Particle Journal</i> , 2010, 28, 3-19. | 1.7 | 25 |
| 69 | Materials for Pharmaceutical Dosage Forms: Molecular Pharmaceutics and Controlled Release Drug Delivery Aspects. <i>International Journal of Molecular Sciences</i> , 2010, 11, 3298-3322. | 4.1 | 168 |
| 70 | Nanomedicine in pulmonary delivery. <i>International Journal of Nanomedicine</i> , 2009, 4, 299. | 6.7 | 378 |
| 71 | Characterization of the <i>In Situ</i> Structural and Interfacial Properties of the Cationic Hydrophobic Heteropolymer, KL ₄ , in Lung Surfactant Bilayer and Monolayer Models at the Air/Water Interface: Implications for Pulmonary Surfactant Delivery. <i>Molecular Pharmaceutics</i> , 2008, 5, 681-695. | 4.6 | 13 |
| 72 | Formulation Challenges of Powders for the Delivery of Small Molecular Weight Molecules as Aerosols. , 2008, , 573-601. | | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Relationships between Equilibrium Spreading Pressure and Phase Equilibria of Phospholipid Bilayers and Monolayers at the Air-Water Interface. <i>Langmuir</i> , 2007, 23, 3809-3819. | 3.5 | 59 |
| 74 | The relationship between water vapor absorption and desorption by phospholipids and bilayer phase transitions. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 377-396. | 3.3 | 40 |
| 75 | Physical Characterization of Component Particles Included in Dry Powder Inhalers. I. Strategy Review and Static Characteristics. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 1282-1301. | 3.3 | 127 |
| 76 | Physical Characterization of Component Particles Included in Dry Powder Inhalers. II. Dynamic Characteristics. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 1302-1319. | 3.3 | 81 |
| 77 | Influence of chitosan type on the properties of extruded pellets with low amount of microcrystalline cellulose. <i>AAPS PharmSciTech</i> , 2007, 8, E99-E109. | 3.3 | 34 |
| 78 | Raman characterization and chemical imaging of biocolloidal self-assemblies, drug delivery systems, and pulmonary inhalation aerosols: A review. <i>AAPS PharmSciTech</i> , 2007, 8, 140. | 3.3 | 57 |
| 79 | Comparison of Bilayer and Monolayer Properties of Phospholipid Systems Containing Dipalmitoylphosphatidylglycerol and Dipalmitoylphosphatidylinositol. <i>Langmuir</i> , 2001, 17, 6622-6632. | 3.5 | 45 |